Lilly's Six Lawsuits Target Black-Market Sellers of Unapproved Retatrutide
Eli Lilly filed six federal lawsuits on August 12, 2026, naming Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide Co. as defendants in cases lodged in California and Texas. The Indianapolis-based company accuses all six of selling products marketed as retatrutide, a once-weekly injectable triple-hormone agonist still in Phase 3 trials for obesity and type 2 diabetes. No regulatory agency in any country has approved the compound for human use, which means Lilly is not defending a marketed product. It is asking federal courts to shut down commercial activity around a molecule that legally does not exist as a medicine. That framing distinguishes these filings from the company's prior suits over unauthorized Zepbound and Mounjaro sales, where an approved product and established supply chain gave Lilly conventional infringement claims. Here, the legal ground is the federal prohibition on selling unapproved drugs and the allegation that "research-use only" labeling conceals consumer-directed commerce.
What the Complaints Allege
Four of the named defendants—Astra Peptides, Legendary Peptides, Texas Peptides, and Lone Star Peptide—advertise retatrutide products under a "research use" disclaimer without requiring a prescription, BioPharma Dive reported. Aesthetic Envy, a California medical-spa chain, promotes retatrutide directly to consumers. Striker Pharmacy has prepared a version of the compound. Lilly's complaint describes the sellers as providing products "in circumstances suggesting human use" despite the research-only labeling, a characterization drawn from Medindia's account of the filings. The company has not publicly disclosed the specific dosage forms or packaging at issue in each case.
Dr. Max Denning, Lilly's Associate Vice President for Global Patient Safety in Cardiometabolic Health, stated that anyone injecting these products "is exposing themselves to a huge amount of risk." Chief Medical Officer Dr. David Hyman called the black-market products "entirely unverified, unapproved and not worth the risk." The FDA separately warned that so-called research-use-only products "are of unknown quality and may be harmful to consumers' health."
The compounding question narrows the legal field for Striker Pharmacy. In June, the FDA stated that retatrutide cannot lawfully be compounded because it is not the subject of a USP monograph, is not a component of any approved drug, and does not appear on the 503A bulks list. CNBC reported that the agency's position leaves no statutory exemption under which a pharmacy could prepare the compound. Striker Pharmacy cannot invoke the shortage-era compounding defense that some pharmacies used for tirzepatide and semaglutide products in 2023 and 2024, because retatrutide was never approved and never appeared on a shortage list.
The Campaign Behind the Docket
The six complaints are one instrument in a wider enforcement push. Lilly said it has reported more than 14,000 websites, advertisements, social-media posts, and product listings marketing retatrutide across more than 100 countries to internet-service providers, e-commerce platforms, and regulators. On August 12, the company also called on payment processors, credit-card companies, shipping firms, and social-media platforms to sever transaction and distribution channels for unauthorized sellers. Lilly's investor-relations statement urged drug regulators and customs agencies to "prioritize enforcement and coordinate across borders to dismantle the criminal networks selling these drugs."
U.S. Customs and Border Protection intercepted more than 690 shipments containing over 31,000 units of illicit GLP-1 products during fiscal 2025. The seizure pace accelerated sharply, with more than 1,400 interceptions recorded in July 2026 alone. Those figures describe a supply pipeline feeding the domestic storefronts Lilly is now suing, though the agency has not broken out retatrutide-specific seizures from the broader GLP-1 category.
The compounding and telehealth channels complicate enforcement. Pharmacies and clinics that began dispensing compounded GLP-1 products during the tirzepatide and semaglutide shortages of 2022 and 2023 have continued operating after the FDA declared those shortages resolved. As eli lilly sues six retatrutide sellers, escalating beyond agency referrals documented, some of those same operators now list retatrutide alongside approved products. The absence of any approval for retatrutide anywhere in the world removes the supply-gap rationale those businesses previously cited.
The defendants now face service of process and the choice to answer or default in federal courts in California and Texas. Lilly has not disclosed the damages it seeks or the specific injunctive relief requested in each complaint. The cases will test whether a drugmaker can obtain court orders halting sales of a compound that no regulator has cleared, and whether the "research-use only" designation provides any shield when the seller operates a consumer-facing website or a medical-spa waiting room. Dr. Denning's patient-safety office at Lilly will monitor adverse-event reports tied to unauthorized products while the litigation proceeds.
Related Peptides Agora analysis examines eli lilly files six federal lawsuits to dismantle the retatrutide 'research-use only' mark, and eli lilly sues six sellers over unapproved retatrutide sales.
